Literature DB >> 26679604

Two c-Myc binding sites are crucial in upregulating the expression of human phospholipid scramblase 1 gene.

Janaki Manoja Vinnakota1, Sathyanarayana N Gummadi2.   

Abstract

Human phospholipid scramblase 1 (hPLSCR1) is a type II endofacial membrane protein which mediates bi-directional transport of phospholipids across the plasma membrane. hPLSCR1, a multifunctional protein with variety of roles in apoptosis, tumor progression, cell signaling and anti-viral defense. The expression of such a multifunctional protein should be under tight regulation. Apart from a single report showing snail mediated down regulation of hPLSCR1, the molecular mechanisms regulating the expression of scramblases are not well elucidated. In this study we identified c-Myc as a transcriptional regulator of hPLSCR1. Transcription factor prediction tool ConSite predicted three binding sites for c-Myc. Reporter gene assays and western blot analysis revealed c-Myc mediated up regulation of hPLSCR1 expression. Deletion construct -790 lacking one c-Myc binding site showed a 27% decrease in promoter activity while deletion construct -469 lacking two c-Myc binding sites showed a 62% decrease in promoter activity. Site directed mutagenesis revealed the importance of c-Myc binding sites from -751 to -756 and -548 to -553 on the promoter of hPLSCR1in transcriptionally regulating the expression of hPLSCR1. The results were further confirmed by shRNA mediated knock down of endogenous c-Myc and in vivo interactions by ChIP assay.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Apoptosis; Human phospholipid scramblase 1; Transcriptional regulation; c-Myc

Mesh:

Substances:

Year:  2015        PMID: 26679604     DOI: 10.1016/j.bbrc.2015.11.131

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Interaction of phospholipid scramblase 1 with the Epstein-Barr virus protein BZLF1 represses BZLF1-mediated lytic gene transcription.

Authors:  Shuichi Kusano; Masanori Ikeda
Journal:  J Biol Chem       Date:  2019-08-21       Impact factor: 5.157

Review 2.  Phospholipid scramblase 1: a protein with multiple functions via multiple molecular interactors.

Authors:  Jessica Dal Col; Marìa Julia Lamberti; Annunziata Nigro; Vincenzo Casolaro; Elisabetta Fratta; Agostino Steffan; Barbara Montico
Journal:  Cell Commun Signal       Date:  2022-06-01       Impact factor: 7.525

3.  THAP11 Functions as a Tumor Suppressor in Gastric Cancer through Regulating c-Myc Signaling Pathways.

Authors:  Jing Zhang; Huahua Zhang; Haiyan Shi; Fenghui Wang; Juan Du; Yu Wang; Yameng Wei; Wanjuan Xue; Dan Li; Yun Feng; Jing Yan; Yi Gao; Jia Li; Jiming Han
Journal:  Biomed Res Int       Date:  2020-08-27       Impact factor: 3.411

4.  Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1-STAT1 loop in lung adenocarcinoma.

Authors:  Wei-Chao Liao; Tsung-Jen Lin; Yu-Chin Liu; Yu-Shan Wei; Guan-Ying Chen; Hsiang-Pu Feng; Yi-Feng Chang; Hsin-Tzu Chang; Chih-Liang Wang; Hsinag-Cheng Chi; Chun-I Wang; Kwang-Huei Lin; Wei-Ting Ou Yang; Chia-Jung Yu
Journal:  Cancer Sci       Date:  2021-11-25       Impact factor: 6.716

5.  The Interferon-Inducible Human PLSCR1 Protein Is a Restriction Factor of Human Cytomegalovirus.

Authors:  Hidetaka Sadanari; Shuichi Kusano; Masaya Takemoto; Tomoki Ishida; Hikaru Otagiri; Tohru Daikoku; Tsugiya Murayama
Journal:  Microbiol Spectr       Date:  2022-02-09

Review 6.  Phospholipid Scramblases: Role in Cancer Progression and Anticancer Therapeutics.

Authors:  Himadri Gourav Behuria; Sabyasachi Dash; Santosh Kumar Sahu
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

7.  Identification and characterization of the novel nuclease activity of human phospholipid scramblase 1.

Authors:  Ulaganathan Sivagnanam; Shweta Narayana Murthy; Sathyanarayana N Gummadi
Journal:  BMC Biochem       Date:  2016-05-20       Impact factor: 4.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.